replic
coronavirus
inhibit
vitro
cyclosporin
wellknown
immunosuppress
drug
bind
cellular
cyclophilin
thu
inactiv
enzymat
cistran
peptidylprolyl
isomeras
function
latter
requir
proper
fold
cellular
protein
protein
sever
virus
summar
present
knowledg
role
cyclophilin
coronaviru
replic
present
data
effect
cyclophilin
singl
nucleotid
polymorph
mutant
replic
human
demonstr
requir
proper
cyclophilin
function
viru
propag
result
defin
cellular
cyclophilin
host
target
inhibit
coronavirus
rang
rel
mild
common
cold
highli
pathogen
sarscov
merscov
virus
perspect
disclos
nonimmunosuppress
cyclosporin
analog
broadli
inactiv
coronaviru
famili
albrecht
von
brunn
sandra
ciesek
brigitt
von
brunn
javier
carbajolozoya
replic
coronavirus
inhibit
vitro
cyclosporin
wellknown
immunosuppress
drug
bind
cellular
cyclophilin
thu
inactiv
enzymat
cistran
peptidylprolyl
isomeras
function
latter
requir
proper
fold
cellular
protein
protein
sever
virus
summar
present
knowledg
role
cyclophilin
coronaviru
replic
present
data
effect
cyclophilin
singl
nucleotid
polymorph
mutant
replic
human
demonstr
requir
proper
cyclophilin
function
viru
propag
result
defin
cellular
cyclophilin
host
target
inhibit
coronavirus
rang
rel
mild
common
cold
highli
pathogen
sarscov
merscov
virus
perspect
disclos
nonimmunosuppress
cyclosporin
analog
broadli
inactiv
coronaviru
famili
coronavirus
cov
infect
varieti
mammalian
speci
includ
bat
mice
cat
bird
human
caus
infect
respiratori
gastrointestin
tract
central
nervou
system
cov
envelop
virus
contain
largest
known
singlestrand
rna
genom
kb
positivesens
orient
divid
four
genera
alpha
beta
sarscov
lineag
b
merscov
lineag
c
gammaand
deltacoronaviru
six
human
cov
name
sarscov
merscov
mainli
target
respiratori
tract
common
cold
caus
hcov
mostli
season
occurr
wherea
known
sinc
sarscov
appear
first
china
caus
worldwid
outbreak
case
death
enorm
socioeconom
impact
aris
interest
cov
led
discoveri
mer
identifi
saudi
arabia
may
merscov
infect
rose
case
death
may
new
outbreak
occur
south
korea
report
case
death
june
individu
place
quarantin
make
largest
outbreak
outsid
saudi
arabia
effect
drug
treatment
avail
neither
common
cold
highli
pathogen
cov
develop
antivir
concentr
develop
proteas
helicas
inhibitor
great
effort
made
discov
antim
agent
screen
defin
drug
librari
although
cov
display
proofread
activ
replic
viral
target
usual
prone
develop
resist
mutat
rather
quickli
therefor
defin
cellular
cofactor
requir
viral
replic
target
rather
intrigu
screen
divers
compound
activ
lundin
et
al
identifi
inhibitor
specif
target
membranebound
coronavir
rna
synthesi
earli
step
viral
replic
use
unbias
highthroughput
proteinprotein
interact
screen
method
identifi
cyclophilin
bind
factor
cov
protein
inhibitor
cyclosporin
csa
broadrang
anticoronavir
agent
csa
bind
inactiv
cypa
cellular
cofactor
viru
propag
summar
accompani
articl
octob
issu
current
opinion
virolog
von
hahn
ciesek
summar
inhibitori
effect
csa
nonimmunosuppress
deriv
thereof
cypa
function
cov
replic
describ
effect
genet
defici
individu
cypa
snp
mutant
replic
indic
requir
correctli
fold
enzymat
groov
cypa
cyclophilin
fkbp
member
two
ubiquit
distribut
ppias
famili
collect
call
immunophilin
import
number
cellular
process
exampl
protein
fold
matur
traffick
signal
transduct
cell
differenti
apoptosi
infect
cypa
cypb
recogn
techniqu
specif
bind
gag
polyprotein
capsid
cypa
demonstr
specif
incorpor
virion
review
bind
aminotermin
domain
capsid
activ
groov
cypa
demonstr
crystal
structur
mutat
analysi
prolinecontain
peptid
substrat
bind
hydrophob
pocket
confer
enzymat
peptidylprolyl
cistran
isomeras
ppias
ec
number
activ
isomeras
function
cyp
identifi
alreadi
first
shown
csa
also
bind
groov
thu
interf
proper
capsid
format
viru
replic
case
hepat
c
viru
hcv
involv
cyp
shown
sever
group
initi
conflict
result
cypa
b
support
hcv
replic
could
clarifi
favor
cypa
import
ppias
activ
complet
independ
featur
csa
bind
cypa
format
trimolecular
complex
cellular
phosphatas
calcineurin
cn
natur
coincid
farreach
consequ
immun
system
cn
normal
dephosphoryl
import
immunolog
transcript
factor
nfat
nuclear
factor
activ
tcell
transloc
nucleu
act
key
regul
tcell
develop
product
cypacsacn
complex
prevent
nfat
dephosphoryl
transloc
nucleu
thu
lead
suppress
immun
system
csa
cyclic
peptid
display
surfac
bind
ppias
groov
cypa
one
complex
cn
figur
intens
effort
made
separ
ppias
block
immunosuppress
function
csa
modifi
side
chain
csa
molecul
allow
develop
nonimmunosuppress
analog
alisporivir
alv
sangliferin
seri
newli
synthes
csa
posit
compound
alisporivir
experienc
substanti
clinic
test
safeti
databas
develop
patient
treat
week
administ
small
number
patient
short
proofofconcept
trial
first
hint
possibl
involv
cyclophilin
name
cypa
sarscov
replic
came
educ
guess
find
demonstr
interact
sarscov
nucleocapsid
n
protein
cypa
surfac
plasmon
reson
biosensor
technolog
parallel
bind
gag
cypa
find
support
proteom
studi
identifi
cypa
one
number
cellular
protein
incorpor
purifi
sarscov
particl
spectrometr
profil
inhibitori
effect
csa
cov
replic
report
sever
laboratori
use
unbias
high
throughput
proteinprotein
interact
screen
method
notic
bind
sever
cyclophilin
sarscov
csa
pancov
inhibitor
includ
sarscov
felin
cov
fcov
serotyp
ii
strain
black
transmiss
gastroenter
viru
tgev
infecti
bronchiti
viru
ibv
beaudett
followup
studi
could
demonstr
least
replic
cypa
cypb
cyclophilin
requir
viru
replic
also
immunophilin
show
interact
partner
virushost
protein
interact
screen
mention
sarscov
test
sensit
drug
could
effect
inhibit
replic
virus
replic
knockdown
cell
line
thu
ppias
activ
cypa
fkbp
seem
crystal
structur
human
cypa
complex
csa
pdb
databas
modifi
code
nonsynonym
ppia
gene
snp
snp
accompani
amino
acid
exchang
introduc
ppia
manipul
cell
line
cypa
shown
bsheet
structur
snp
amino
acid
strongli
slightli
affect
cov
replic
ball
format
color
red
blue
respect
activ
site
residu
depict
orang
csa
bind
ppias
activ
pocket
cypa
shown
green
calcineurinbind
surfac
cypacsa
complex
indic
schemat
requir
cov
replic
substitut
current
interpret
two
class
ppias
act
differ
viral
protein
replic
inhibit
csa
log
also
shown
gfpexpress
sarscov
mhv
mous
hepat
viru
well
merscov
studi
specif
cyclophilin
could
attribut
sarscov
replic
replic
highli
pathogen
cat
cov
felin
infecti
periton
viru
fipv
shown
sensit
csa
rather
interestingli
perform
csa
inhibit
experi
anim
cov
also
find
inhibit
two
fcov
serotyp
unpublish
rgen
thiel
person
commun
tgev
ibv
beaudett
strain
unpublish
christel
herrler
person
commun
cyclophilin
shown
play
central
role
neuron
program
cell
death
cypd
knockdown
csa
inhibit
csa
combin
cypd
act
inhibitor
mitochondri
permeabil
transit
pore
recent
shown
replic
cell
depend
cyclophilin
cypa
cypb
human
hepatocellular
carcinoma
cell
deriv
support
replic
number
virus
includ
hcv
util
cypa
variant
cell
line
origin
construct
analysi
hcv
infect
variant
use
cypa
knockdown
nontarget
control
wtcypa
cypa
knockdown
reconstitut
cypa
mutant
encod
individu
nonsynonym
ppia
gene
snp
amino
acid
exchang
see
also
figur
hcv
viral
growth
behavior
shown
depend
protein
stabil
individu
snp
variant
although
mrna
level
determin
qpcr
analysi
compar
cypa
variant
protein
level
reduc
appear
nearli
absent
infect
experi
rel
cypa
mrna
express
level
analyz
variou
cell
line
qpcr
relat
hous
keep
gene
level
set
figur
cypa
mrna
level
nontarget
control
shctr
variant
slightli
decreas
level
wtcypareconstitut
shcypakd
cell
increas
shcypakd
cell
ppia
mrna
close
background
confirm
knockdown
effici
although
complet
order
assess
growth
properti
variou
cell
line
infect
moi
viru
grown
h
figur
judg
luciferas
protein
express
level
rlu
viru
grew
best
cell
twofold
increas
shcypakd
wtcypa
nontarget
shctr
cell
shcypakd
cell
viru
replic
decreas
factor
h
h
timepoint
respect
case
mutant
viru
growth
slightli
decreas
compar
shcypakd
wtcypa
shctr
cell
interestingli
replic
almost
complet
abolish
case
shcypakd
cell
assess
viral
replic
level
essenti
n
protein
product
virusinfect
cell
moi
western
blot
analysi
viral
n
protein
two
day
pi
perform
figur
n
protein
level
similar
shctr
shcypakd
wtcypa
reconstitut
cell
shcypakd
cell
n
almost
absent
confirm
requir
cypa
replic
genet
variat
host
gene
involv
viru
infect
also
human
diseas
highest
clinic
interest
protein
repres
potenti
molecul
hosttarget
therapeut
agent
hta
broadrang
antivir
activ
even
case
rare
genet
variant
analysi
might
give
import
clue
diseas
mechan
case
hcv
understand
function
architectur
type
iii
ifn
genom
region
snp
improv
knowledg
pathogenet
mechan
hcv
infect
howev
studi
effect
snp
mutat
infect
interpret
care
consid
composit
cohort
differ
diseas
progress
durat
time
followup
studi
cov
host
snp
data
avail
might
give
clue
resist
promot
viral
infect
exampl
snp
gene
involv
innat
immun
correl
sarscov
load
initi
phase
infect
g
promot
polymorph
gene
encod
dcsign
correl
clinicalpatholog
outcom
serolog
confirm
sar
patient
genotyp
associ
lower
standard
lactatedehydrogenas
ldh
level
compar
genotyp
carri
patient
chanc
poorer
prognosi
higher
ldh
level
cat
sever
snp
describ
tnfa
ifng
gene
found
associ
outcom
fcov
infect
suscept
resist
felin
infecti
periton
fip
immunemedi
highli
lethal
diseas
without
effect
therapi
prevent
genomewid
associ
studi
identifi
snp
signific
effect
antibodi
level
ibv
chicken
demonstr
inhibitori
potenti
csa
nonimmunosuppress
deriv
effect
inhibitor
cov
replic
other
introduc
cyclophilin
target
compound
possibl
host
target
prevent
cov
infect
use
cypa
knockdown
knockout
mutant
cell
line
shown
requir
protein
cov
replic
variant
close
agreement
hcv
replic
studi
cell
line
discuss
author
first
three
function
respect
suppress
viru
replic
amino
acid
exchang
locat
near
isomeras
activ
site
wherea
nonfunct
second
mutat
set
locat
remot
see
figur
destabil
cypa
identifi
underli
mechan
result
nearcomplet
intracellular
cypa
deplet
infect
mutant
cell
line
cypa
mrna
level
detect
qpcr
analysi
test
found
except
mutant
quit
compar
reason
assum
similar
mechan
reduc
differenti
replic
behavior
coronavirus
even
though
could
expect
deplet
destabil
highli
promin
cypa
housekeep
gene
would
detriment
cell
growth
clear
mutat
cell
line
prolifer
quit
normal
reason
could
either
oppos
knockout
knockdown
cypa
complet
activ
residu
molecul
suffic
cell
growth
ppias
function
could
overtaken
isomeras
alreadi
shown
prolyl
isomeras
type
case
cypa
prolyl
isomeras
requir
propag
hcv
cov
hcv
hcov
studi
clear
express
correctli
fold
stabl
cypa
essenti
blockad
activ
groov
csa
cyclophilin
requir
coronaviru
replic
von
brunn
et
al
nonessenti
amino
acid
penicillin
streptomycin
cell
harbor
small
hairpin
rna
shrna
construct
kept
presenc
blasticidin
mgml
mgml
addit
ad
cell
carri
pwpiencod
cypa
variant
use
qpcr
standard
cyclophilin
express
b
replic
measur
determin
renilla
luciferas
activ
cell
extract
h
pi
valu
given
rel
light
unit
rlu
c
nprotein
express
replic
measur
shcypakd
nontarget
control
shctr
wtcypa
reconstitut
cell
qpcrwestern
blot
method
materi
use
describ
deriv
block
enzymat
function
essenti
replic
virus
coronavirus
clarifi
whether
viral
protein
apart
cypa
binder
nucleocapsid
requir
prolinedirect
bind
ppias
activ
cypa
underli
mechan
involv
viru
replic
due
fact
cypa
snp
rare
human
popul
cypa
effect
inhibit
csa
nonimmunosuppress
deriv
thereof
even
intrigu
put
effort
develop
compound
broadspectrum
anticoronavir
drug
sever
virus
includ
coronavirus
hcv
requir
function
cypa
replic
snp
variant
caus
amino
acid
exchang
around
ppias
activ
site
destabil
protein
contribut
lower
viru
replic
role
cov
replic
need
clarifi
cypa
repres
import
host
factor
whose
activ
effici
block
hta
like
csa
nonimmunosuppress
deriv
thereof
author
disclos
conflict
interest
